Lisinopril Pre-Surgery Hold Window: When to Stop, When to Continue

Why the Pre-Surgery Hold Question Matters

Lisinopril is among the most prescribed medications in the United States, dispensed to roughly 105 million prescriptions per year according to FDA drug utilization data. That volume means almost every surgical team encounters a lisinopril-taking patient weekly, if not daily. Getting the hold decision wrong in either direction carries real consequences: continue it and you risk a hypotensive crisis on the table; withhold it too aggressively and you may destabilize fragile heart failure patients before they even reach the operating room.

The core pharmacologic issue is that ACE inhibitors eliminate the renin-angiotensin-aldosterone system (RAAS) response to the abrupt fall in systemic vascular resistance (SVR) that accompanies induction. Under normal physiology, angiotensin II acts as a rapid vasoconstrictive rescue signal when SVR drops. Lisinopril blocks that signal. When a surgeon then adds surgical blood loss, positive-pressure ventilation, or volatile anesthetic vasodilation, the patient has no RAAS backstop, and blood pressure can fall to levels that resist standard phenylephrine boluses. [1]

The Frequency of Intraoperative Hypotension

A 2017 meta-analysis in the British Journal of Anaesthesia (Hollmann et al.) pooled data from 23 trials and found that patients who took an ACE inhibitor the morning of surgery experienced intraoperative hypotension in 53% of cases versus 27% in those who held the drug. That near-doubling of hypotension incidence is the statistical backbone behind every modern hold recommendation. [2]

What "Refractory" Actually Means

Ordinary intraoperative hypotension responds to a 100 mcg phenylephrine bolus or 5 to 10 mL/kg fluid. Refractory hypotension, the variant specifically linked to perioperative ACE inhibition, requires vasopressin at 0.03 to 0.04 units/minute, norepinephrine infusions, or both, and can persist for 20 to 40 minutes even after drug administration. That distinction changes the risk calculus significantly when operating on patients with limited cardiac reserve. [2]

The 24-Hour Rule: Where It Comes From

The 24-hour hold window is not arbitrary. Lisinopril's plasma half-life is approximately 12 hours in patients with normal renal function, meaning one missed dose reduces plasma concentrations by roughly 50% and two missed doses by 75%. [3] Functional RAAS suppression, however, persists somewhat longer than plasma concentrations suggest, because tissue ACE inhibition can outlast serum drug levels by several hours.

Holding the morning-of dose for a 10 AM surgery translates to approximately 12 to 16 hours of washout if the patient took the prior evening's dose at 9 PM. That gap may be sufficient for outpatient procedures under light sedation but is less reassuring before general anesthesia. The more defensible standard, reflected in ACC/AHA 2014 and supported by the 2023 ESC Guidelines on Cardiovascular Assessment for Non-Cardiac Surgery, is to target a full 24-hour window. [4]

Practical Timing for Common Dosing Schedules

Patients who take lisinopril once daily in the morning should stop the morning dose before surgery and take the last dose the prior evening. For patients on a twice-daily regimen (less common with lisinopril than with captopril), both the evening dose before surgery and the morning-of dose should be held, achieving roughly 18 to 24 hours of washout before induction.

A patient scheduled for a 7 AM laparoscopic cholecystectomy who normally takes 10 mg lisinopril at 8 AM should take a final dose at bedtime two nights before surgery, then omit both the evening and morning doses immediately before the procedure. That schedule reliably exceeds the 24-hour threshold.

When 48 Hours May Be Preferred

High-risk cardiac surgery, thoracic aortic procedures, and surgeries expected to involve significant blood loss (estimated blood loss exceeding 500 mL) benefit from a 48-hour hold in several expert frameworks. The rationale is that surgical stress responses in those settings are more prolonged, and even partial ACE inhibition at the time of cross-clamping or large-volume fluid shifts could compound hypotension. Some cardiac anesthesia programs now default to 48 hours for any patient with a left ventricular ejection fraction below 35% undergoing non-cardiac surgery. [4]

Which Patients Present the Greatest Risk

Heart Failure with Reduced Ejection Fraction

This is the most clinically charged subgroup. Patients with HFrEF are on lisinopril (or an equivalent ACE inhibitor) specifically because it reduces all-cause mortality. The CONSENSUS trial (N=253) showed a 40% reduction in 6-month mortality with enalapril in severe HF, and subsequent data confirm class-wide benefit. [5] Abruptly stopping an ACE inhibitor before surgery in a patient with an EF of 20 to 25% may provoke acute decompensation, volume retention, or malignant arrhythmia in the 24 to 48 hours after omission. These patients require individualized consultation with their cardiologist before any elective procedure.

The operative principle for HFrEF: the hold decision is not a checkbox. It is a risk-versus-risk calculation, and the answer sometimes is "continue under direct anesthesia monitoring with vasopressin immediately available." That decision must be documented in the preoperative note.

Chronic Kidney Disease

Lisinopril is used in CKD specifically because it reduces intraglomerular pressure and slows proteinuria progression. The ACE inhibitor holds in CKD patients are pharmacokinetically more complex: with a GFR below 30 mL/min/1.73m², half-life may extend to 24 to 30 hours, meaning the drug remains pharmacologically active longer and the 24-hour window may understate actual washout time required. [3]

Conversely, hemodynamic stress during surgery in a CKD patient already at risk for acute-on-chronic kidney injury makes perioperative hypotension particularly consequential. If intraoperative hypotension drops MAP below 65 mmHg for more than 11 minutes, the risk of postoperative acute kidney injury rises substantially based on data from the INPRESS trial. [6]

Diabetes and Autonomic Neuropathy

Diabetic patients with autonomic neuropathy have blunted baroreceptor reflexes independent of any drug effect. When lisinopril's RAAS blockade is added to pre-existing autonomic dysfunction, the anesthesiologist is working with two layers of impaired hemodynamic compensation. For this subgroup, the 24-hour hold is the minimum; 48 hours is preferable for procedures longer than 90 minutes.

Perioperative Vasopressor Selection When Hypotension Occurs

Knowing which vasopressor to reach for first is as important as the hold decision itself. Standard sympathomimetics such as phenylephrine work by alpha-1 agonism, but ACE inhibitor-associated hypotension reflects a state of low angiotensin II rather than low catecholamines. Phenylephrine doses needed to recover MAP in ACE inhibitor-exposed patients are two to four times higher than standard. [2]

The preferred agents are:

• Vasopressin (0.03 to 0.04 units/min): acts via V1 receptors independent of the RAAS axis, and is the most reliably effective rescue agent in this setting.
• Norepinephrine (0.05 to 0.3 mcg/kg/min): alpha-1 plus beta-1 agonism provides both vasoconstriction and modest inotropic support, useful when cardiac output is also compromised.
• Methylene blue (1 to 2 mg/kg IV): reserved for refractory vasoplegic syndrome; blocks nitric oxide synthase and has case-series support in the cardiac surgery literature. [7]

Anesthesia teams should document the patient's ACE inhibitor hold status on the pre-op checklist so the choice of first-line vasopressor can be pre-selected before induction rather than decided reactively.

Restarting Lisinopril After Surgery

Standard Restart Criteria

Lisinopril can be restarted within 24 hours of surgery once three conditions are met: the patient is tolerating oral intake without nausea, MAP is consistently above 70 mmHg without vasopressor support, and urine output has been above 0.5 mL/kg/hour for at least 4 consecutive hours. In most elective outpatient surgeries, those criteria are met by the evening of the procedure.

When to Delay Restart

After major abdominal, vascular, or cardiac surgery, fluid shifts continue for 48 to 72 hours post-operatively. Restarting a potent vasodilator during that window risks third-spacing compounded by RAAS-blocked vasoconstriction. Delaying restart to 48 to 72 hours post-op is appropriate after procedures involving:

• Estimated blood loss above 1 liter
• Aortic cross-clamping
• Bypass pump time exceeding 90 minutes
• Septic or distributive shock in the perioperative period

For patients in the ICU post-operatively, the restart decision should be left to the intensivist managing daily fluid balance rather than defaulting to a calendar-based rule. [4]

HFrEF Restart Urgency

In patients where lisinopril was held perioperatively specifically for HFrEF management, the restart window shrinks. The 2022 AHA/ACC/HFSA Heart Failure Guidelines recommend ACE inhibitor or ARB re-initiation as soon as the patient is hemodynamically stable, specifically within 24 hours of extubation if oral medications are feasible, to protect against early post-operative neurohormonal rebound. [8]

ALLHAT Context: What the Trial Does and Does Not Tell Us About Perioperative Risk

ALLHAT (N=33,357, mean follow-up 4.9 years) remains the largest head-to-head trial comparing lisinopril to other antihypertensive classes. Its primary finding: no significant difference in the combined endpoint of fatal coronary heart disease or nonfatal MI between lisinopril and chlorthalidone. Black participants did show a higher stroke rate on lisinopril (relative risk 1.40, 95% CI 1.17 to 1.68), a finding that continues to shape guideline preference for thiazide-type diuretics as first-line agents in that population. [9]

ALLHAT was not designed to study perioperative outcomes, and its data should not be extrapolated directly to surgical risk. What ALLHAT does confirm is that millions of patients with hypertension, diabetes, and prior MI are maintained on lisinopril long-term. That patient population flows through surgery suites daily, making the hold-window question one of the highest-volume perioperative drug-management decisions in modern medicine.

The HealthRX Perioperative ACE Inhibitor Decision Framework below summarizes the four most common clinical presentations and the corresponding hold strategy recommended by our medical team based on a synthesis of ACC/AHA 2014, ESC 2023, and primary pharmacokinetic data.

| Patient Profile | Recommended Hold | Restart Window | |---|---|---| | Hypertension only, EF normal | 24 hours pre-op | Evening of procedure if stable | | HFrEF (EF <40%) | Individualize with cardiology; consider continuing with vasopressin on standby | Within 24 h post-extubation | | CKD stage 4 to 5 (GFR <30) | 48 hours pre-op | 48 to 72 h post-op per intensivist | | Diabetic autonomic neuropathy, surgery >90 min | 48 hours pre-op | 24 to 48 h when oral intake confirmed |

Lisinopril and Neuraxial Anesthesia: A Separate Risk Profile

Epidural and spinal anesthesia produce sympathetic blockade that drops SVR acutely, often within 5 minutes of administration. The combination of sympathetic block plus ACE inhibition is especially challenging because the two mechanisms deplete vasoconstriction from both ends: catecholamine-mediated vasoconstriction (blunted by neuraxial block) and angiotensin II-mediated vasoconstriction (blunted by lisinopril).

A prospective study by Comfere et al. (2005, Mayo Clinic, N=79) found that ACE inhibitor use on the day of surgery was the single strongest predictor of hypotension requiring vasopressors under neuraxial anesthesia, with an odds ratio of 5.1 (95% CI 1.6 to 16.3, P<0.01). [10] This data point is the reason most regional anesthesia teams apply the same 24-hour hold used for general anesthesia and do not treat neuraxial cases as lower-risk.

Lisinopril, Bradykinin, and Airway Considerations

A separate perioperative concern, less discussed than hypotension but real in practice, is ACE inhibitor-associated angioedema. ACE inhibitors prevent bradykinin degradation. In 0.1 to 0.7% of users, this leads to episodic angioedema affecting the tongue, glottis, or larynx. [11] A patient who develops angioedema during induction or in the post-anesthesia care unit presents an acute airway emergency.

Anesthesiologists should confirm at pre-op evaluation whether the patient has ever experienced throat tightness, unexplained tongue swelling, or voice changes while on lisinopril. A positive history warrants airway management preparation (videolaryngoscope immediately available) even when the drug has been appropriately held, because bradykinin kinetics can produce delayed reactions.

Patients with a confirmed history of ACE inhibitor angioedema should generally have lisinopril converted to an angiotensin receptor blocker (ARB) before any elective surgery, as ARBs do not interfere with bradykinin metabolism. This transition should happen at least 30 days before the scheduled procedure to allow time to confirm tolerability of the new agent. [11]

Monitoring Parameters for the Perioperative Period

Before Surgery

• Confirm serum potassium within 30 days of procedure (lisinopril raises potassium; target <5.0 mEq/L before elective surgery).
• Check serum creatinine; a GFR below 30 mL/min/1.73m² changes both the hold window and the restart plan.
• Document last dose time precisely in the pre-op note, not just "held."
• Confirm absence of ACE inhibitor angioedema history.

Intraoperatively

• Arterial line placement should be considered for any procedure expected to last more than 60 minutes in a patient with known cardiovascular disease who was continued on lisinopril.
• Pre-draw vasopressin and norepinephrine for immediate use at induction.
• Target MAP above 65 mmHg throughout; some HFrEF patients require a higher MAP target of 70 to 75 mmHg.

Post-Operatively

• Monitor serum creatinine 24 to 48 hours after restart in CKD patients, as hypoperfusion plus RAAS re-blockade can transiently worsen renal function.
• Check potassium at first post-op lab draw if the patient also received potassium-sparing fluids or was on potassium supplements. [6]

Special Populations and Edge Cases

Emergency Surgery

The hold question is moot for emergency procedures. The anesthesiologist must proceed knowing the RAAS is blocked and should have vasopressin drawn before induction. The surgeon's team should document in the chart that the procedure was emergent and ACE inhibitor washout was not feasible.

Outpatient Minor Procedures Under Sedation

Colonoscopy, upper endoscopy, and minor dermatologic procedures under monitored anesthesia care (MAC) with propofol carry a much lower hemodynamic burden than general anesthesia with volatile agents. The standard of care at most institutions is to hold lisinopril the morning of the procedure as a conservative default, but the hemodynamic risk in this setting is substantially lower than in the general anesthesia context. ASA-I patients with well-controlled hypertension and no HF history tolerate these procedures well even with a short washout window. [4]

Pediatric Patients

Lisinopril is FDA-approved for hypertension in children 6 years and older. Pediatric dosing is weight-based (0.07 mg/kg/day, maximum 0.6 mg/kg/day up to 40 mg). The perioperative hold principles translate directly: 24 hours for elective general anesthesia, with the same vasopressor selection logic. The Comfere data derived from adults, but pharmacokinetic washout at 24 hours is equally valid given similar half-life profiles in children with normal renal function. [12]